Assignee profile:

Bavarian Nordic A/S

City:

Hellerup

Country:

Denmark

Published Applications:

24

Last publication date:

2026-03-19

Patent Grants:

11

Last grant date:

2026-06-09

Top Inventors for applications by Bavarian Nordic A/S

These are the the leading inventors for applications assigned to Bavarian Nordic A/S:

Recent patent applications by Bavarian Nordic A/S

Bavarian Nordic A/S based in Hellerup, DK has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2026-03-19
US20260078353A1
Chemistry; metallurgy

Mammalian Cell Line for the Production of Modified Vaccinia Virus Ankara (MVA)

#2 | 2025-12-25
US20250387463A1
Human necessities

Recombinant Modified saRNA (VRP) and Vaccinia Virus Ankara (MVA) Prime-Boost Regimen

#3 | 2025-02-13
US20250049903A1
Human necessities

Therapy for Modulating Immune Response with Recombinant MVA Encoding IL-12

#4 | 2025-01-02
US20250002606A1
Chemistry; metallurgy

Combination Therapy for Treating Cancer with an Antibody and Intravenous Administration of a Recombinant MVA

#5 | 2024-11-28
US20240392257A1
Chemistry; metallurgy

Utilization of Micro-RNA for Downregulation of Cytotoxic Transgene Expression by Modified Vaccinia Virus Ankara (MVA)

#6 | 2024-08-15
US20240269254A1
Human necessities

Combination Therapy for Treating Cancer with an Intravenous Administration of a Recombinant MVA and an Immune Checkpoint Antagonist or Agonist

#7 | 2023-07-27
US20230233670A1
Human necessities

A Recombinant Modified Vaccinia Virus (MVA) Vaccine Against Coronavirus Disease

#8 | 2023-06-22
US20230190922A1
Human necessities

Recombinant MVA Viruses for Intratumoral and/or Intravenous Administration for Treating Cancer

#9 | 2023-04-13 ✅ Patent 12,648,992 granted on 2026-06-09
US20230114464A1
Human necessities

Conditions Improving Poxvirus Stability

#10 | 2023-02-23
US20230059344A1
Chemistry; metallurgy

Medical Uses of 4-1BBL Adjuvanted Recombinant Modified Vaccinia Virus Ankara (MVA)

#11 | 2022-08-11 ✅ Patent 11,723,964 granted on 2023-08-15
US20220249636A1
Human necessities

Combination therapy for treating cancer with an antibody and intravenous administration of a recombinant MVA

#12 | 2022-01-06 ✅ Patent 12,390,515 granted on 2025-08-19
US20220000997A1
Human necessities

Therapy for Treating Cancer with an Intratumoral or Intravenous Administration of a Recombinant MVA Encoding 4-1BBL (CD137L) and/or CD40L

#13 | 2021-12-23
US20210393766A1
Human necessities

Recombinant Modified Vaccinia Virus Ankara (MVA) Foot and Mouth Disease Virus (FMDV) Vaccine

#14 | 2021-11-04 ✅ Patent 11,654,189 granted on 2023-05-23
US20210338788A1
Human necessities

Compositions and methods for enhancing the stability of transgenes in poxviruses

#15 | 2021-09-30
US20210299236A1
Human necessities

Methods and Compositions for Enhancing Vaccine Immune Responses

#16 | 2021-07-08 ✅ Patent 11,571,471 granted on 2023-02-07
US20210205439A1
Human necessities

Recombinant modified vaccinia virus ankara (MVA) equine encephalitis virus vaccine

#17 | 2021-07-08
US20210205429A1
Human necessities

Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of an Immune Checkpoint Inhibitor

#18 | 2021-07-01
US20210196814A1
Human necessities

Recombinant Modified Vaccinia Virus Ankara (MVA) Respiratory Syncytial Virus (RSV) Vaccine

#19 | 2021-06-24 ✅ Patent 12,150,988 granted on 2024-11-26
US20210187100A1
Human necessities

Storage improved poxvirus compositions

#20 | 2020-10-15 ✅ Patent 12,644,125 granted on 2026-06-02
US20200325477A1
Chemistry; metallurgy

Compositions and Methods for Inducing an Enhanced Immune Response Using Poxvirus Vectors

#21 | 2020-10-01 ✅ Patent 11,273,211 granted on 2022-03-15
US20200306352A1
Human necessities

Combination therapy for treating cancer with an intravenous administration of a recombinant MVA and an antibody

#22 | 2020-08-27 ✅ Patent 11,338,030 granted on 2022-05-24
US20200268872A1
Human necessities

Multivalent recombinant modified vaccinia virus ankara (MVA) vector encoding filovirus immunogens

#23 | 2020-06-04 ✅ Patent 10,946,089 granted on 2021-03-16
US20200171142A1
Human necessities

Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine

#24 | 2018-08-02 ✅ Patent 11,753,652 granted on 2023-09-12
US20180216134A1
Chemistry; metallurgy

Cassette encoding a FPV/brachyury fusion protein

Also check out Bavarian Nordic A/S's (Hellerup, Denmark) applicant profile with 13 patent applications submitted.

AssigneeID:

164166 ⎘